Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004188489 | SCV003681467 | uncertain significance | not specified | 2022-05-25 | criteria provided, single submitter | clinical testing | The c.5116A>G (p.K1706E) alteration is located in exon 23 (coding exon 23) of the STARD9 gene. This alteration results from a A to G substitution at nucleotide position 5116, causing the lysine (K) at amino acid position 1706 to be replaced by a glutamic acid (E). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV003906595 | SCV004724456 | likely benign | STARD9-related disorder | 2022-09-19 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |